InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（1 笔）
内部人交易记录
高级管理人员已披露买入
2
已披露卖出
1
T+90 胜率
100%
T+90 平均收益
+15.7%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the detailed record of transactions filed by Barthelemy Nicolas, 董事. Insider active across 6 companies, notably REPLIGEN CORP. Aggregated, 15 disclosures have been published. Split: 2 buys · 1 sell. Total volume traded: €577k. Activity tracked since 13 May 2021. The latest transaction was disclosed on 15 May 2025 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Barthelemy Nicolas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报15 总计
973 股0Common StockSEC:0000950170-25-075705:0
1,200 股@ US$125.4549.9% 占其流量Common StockSEC:0000950170-24-073840:0
标准退出：2024年9月12日 (T+90)
701 股0Common StockSEC:0000950170-24-062600:0
686 股0Common StockSEC:0000899243-23-013668:0
9,082 股@ US$23.3346.3% 占其流量Common StockSEC:0001214659-22-014161:0
1,379 股Common Stock, par value $0.001SEC:0001562180-22-005191:0
534 股0Common StockSEC:0000899243-22-020279:0
8,550 股@ US$29.2510.014% mcap100.0% 占其流量Common StockSEC:0001214659-22-006826:0
标准退出：2022年8月9日 (T+90)
20,993 股@ US$3.740.0072% mcap82.1% 占其流量Common StockSEC:0001162194-22-000027:0
5,000 股@ US$3.430.0016% mcap17.9% 占其流量Common StockSEC:0001162194-22-000025:0
3,491 股0Common StockSEC:0001214659-22-002210:0
1,285 股@ US$128.18100.0% 占其流量Common StockSEC:0000899243-21-042393:0
6,000 股@ US$39.63100.0% 占其流量Common Stock, par value $0.001SEC:0001104659-21-085908:0
10,342 股0Common StockSEC:0001162194-21-000063:0
457 股0Common StockSEC:0000899243-21-019710:0
15 条申报中的 15 条
About Barthelemy Nicolas
BARTHELEMY NICOLAS is Administrateur, Vice-Président du Développement Corporatif. He has 15 filings in total, and in the recent filings we hold, the period runs from 2021-05-17 to 2025-05-21, with EUR 378087 of buys and EUR 199260 of sells, and the modal transaction nature is Attribution. He is associated with REPLIGEN CORP, Twist Bioscience Corp, Repligen CORP, 908 Devices Inc., Standard Biotools INC. and Fluidigm CORP.
